Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dorzagliatin (HMS5552) 4-Week Study in T2DM
NCT02386982Phase 1Completed
- Sponsor
- Hua Medicine
- Start
- Mar 2015
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dorzagliatin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Hua Medicine. Primary endpoints: Beta cell function at 4 weeks, Glycated Hemoglobin A1c at 4 weeks and 1 more. Started Mar 2015; status: completed.
02
Drugs
dorzagliatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02386982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02386982.